Feasibility Trial of Extracorporeal Iron Purification in Patients With Myelodysplastic Syndrome or Myelofibrosis

Exclusion Criteria

• •Patients with primary hemochromatosis (transferrin saturation coefficient CS-Tf \> 45%).
• •Patients with a contraindication to the use of MEX-CD1: weight \< 30 kg, iron deficiency.
• •Patients with a known allergy or contraindication to heparin or citrate.
• •Patients undergoing azacitidine or other chemotherapy (or considered as such) for myelodysplastic syndrome or myelofibrosis.
• •Patient who received treatment with luspatercept or erythropoietin (EPO) during the month prior to inclusion.
• •Patients with indications for allogeneic bone marrow transplantation.
• •Patients with a known allergy to shellfish (MEX-CD1 contains chitosan of animal origin) or to one of the other components of MEX-CD1.
• •Patients with a peripheral vascular access that is difficult to access or that needs to be preserved.
• •Patients participating in other interventional research that could interfere with the results of the study.
• •Patients under legal protection or unable to express their consent.
• •Patients under psychiatric care.
• •Patient deprived of liberty by judicial or administrative decision.
• •Pregnant or breast-feeding women.